Ensysce Biosciences (ENSCW) Liabilities and Shareholders Equity (2017 - 2025)

Ensysce Biosciences (ENSCW) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $7.5 million in Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $7.5 million, up 33.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $20.8 million (down 8.9% YoY), and the FY2025 annual result was $7.5 million, up 33.15% from the prior year.
• Liabilities and Shareholders Equity grew to $7.5 million in Q4 2025 per ENSCW's latest filing, from $3.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $16.4 million in Q4 2021 and troughed at $2.7 million in Q4 2023.
• A 5-year average of $7.1 million and a median of $6.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 4566.58% in 2021 and fell as far as 78.93% in 2021.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $16.4 million in 2021, then plunged by 64.15% to $5.9 million in 2022, then sank by 53.98% to $2.7 million in 2023, then soared by 106.69% to $5.6 million in 2024, then jumped by 33.15% to $7.5 million in 2025.
• Business Quant data shows ENSCW's Liabilities and Shareholders Equity at $7.5 million in Q4 2025, $3.2 million in Q3 2025, and $5.6 million in Q2 2025.